Loading...

IDEXX Laboratories

WBAG:IDXX
Snowflake Description

Proven track record with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IDXX
WBAG
$24B
Market Cap
  1. Home
  2. AT
  3. Healthcare
Company description

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The last earnings update was 75 days ago. More info.


Add to Portfolio Compare Print
IDXX Share Price and Events
7 Day Returns
1.8%
WBAG:IDXX
-1.5%
Europe Medical Equipment
-0.2%
AT Market
1 Year Returns
23.8%
WBAG:IDXX
4.1%
Europe Medical Equipment
-5%
AT Market
IDXX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IDEXX Laboratories (IDXX) 1.8% 5.4% 25.9% 23.8% - -
Europe Medical Equipment -1.5% 1.1% 4.3% 4.1% 60.7% 91.8%
AT Market -0.2% 1.9% -5.4% -5% 40.4% 27.4%
1 Year Return vs Industry and Market
  • IDXX outperformed the Medical Equipment industry which returned 4.1% over the past year.
  • IDXX outperformed the Market in Austria which returned -5% over the past year.
Price Volatility
IDXX
Industry
5yr Volatility vs Market

Value

 Is IDEXX Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of IDEXX Laboratories to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for IDEXX Laboratories.

WBAG:IDXX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year AT Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WBAG:IDXX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AT Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.869 (1 + (1- 21%) (4.62%))
0.934
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.51% + (0.934 * 5.96%)
6.07%

Discounted Cash Flow Calculation for WBAG:IDXX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for IDEXX Laboratories is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WBAG:IDXX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.07%)
2020 444.90 Analyst x2 419.42
2021 499.18 Est @ 12.2% 443.65
2022 542.57 Est @ 8.69% 454.60
2023 576.42 Est @ 6.24% 455.30
2024 602.47 Est @ 4.52% 448.63
2025 622.46 Est @ 3.32% 436.97
2026 637.86 Est @ 2.47% 422.14
2027 649.89 Est @ 1.89% 405.47
2028 659.46 Est @ 1.47% 387.88
2029 667.27 Est @ 1.18% 370.00
Present value of next 10 years cash flows $4,244.07
WBAG:IDXX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $667.27 × (1 + 0.51%) ÷ (6.07% – 0.51%)
$12,053.34
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,053.34 ÷ (1 + 6.07%)10
$6,683.61
WBAG:IDXX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,244.07 + $6,683.61
$10,927.68
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,927.68 / 86.01
$127.06
WBAG:IDXX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in WBAG:IDXX represents 0.88507x of NasdaqGS:IDXX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88507x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 127.06 x 0.88507
€112.45
Value per share (EUR) From above. €112.45
Current discount Discount to share price of €251.43
= -1 x (€251.43 - €112.45) / €112.45
-123.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of IDEXX Laboratories is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IDEXX Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IDEXX Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WBAG:IDXX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $4.51
NasdaqGS:IDXX Share Price ** NasdaqGS (2019-07-15) in USD $284.08
Europe Medical Equipment Industry PE Ratio Median Figure of 59 Publicly-Listed Medical Equipment Companies 31.81x
Austria Market PE Ratio Median Figure of 54 Publicly-Listed Companies 14.54x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IDEXX Laboratories.

WBAG:IDXX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IDXX Share Price ÷ EPS (both in USD)

= 284.08 ÷ 4.51

63.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IDEXX Laboratories is overvalued based on earnings compared to the Europe Medical Equipment industry average.
  • IDEXX Laboratories is overvalued based on earnings compared to the Austria market.
Price based on expected Growth
Does IDEXX Laboratories's expected growth come at a high price?
Raw Data
WBAG:IDXX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 63.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
12.6%per year
Europe Medical Equipment Industry PEG Ratio Median Figure of 41 Publicly-Listed Medical Equipment Companies 2.44x
Austria Market PEG Ratio Median Figure of 33 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

WBAG:IDXX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 63.03x ÷ 12.6%

4.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IDEXX Laboratories is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on IDEXX Laboratories's assets?
Raw Data
WBAG:IDXX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.60
NasdaqGS:IDXX Share Price * NasdaqGS (2019-07-15) in USD $284.08
Europe Medical Equipment Industry PB Ratio Median Figure of 139 Publicly-Listed Medical Equipment Companies 3.23x
Austria Market PB Ratio Median Figure of 62 Publicly-Listed Companies 1.22x
WBAG:IDXX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IDXX Share Price ÷ Book Value per Share (both in USD)

= 284.08 ÷ 0.60

474.11x

* Primary Listing of IDEXX Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IDEXX Laboratories is overvalued based on assets compared to the Europe Medical Equipment industry average.
X
Value checks
We assess IDEXX Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. IDEXX Laboratories has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is IDEXX Laboratories expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IDEXX Laboratories expected to grow at an attractive rate?
  • IDEXX Laboratories's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • IDEXX Laboratories's earnings growth is expected to exceed the Austria market average.
  • IDEXX Laboratories's revenue growth is expected to exceed the Austria market average.
Annual Growth Rates Comparison
Raw Data
WBAG:IDXX Future Growth Rates Data Sources
Data Point Source Value (per year)
WBAG:IDXX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 12.6%
WBAG:IDXX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 9.8%
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 18.3%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Austria Market Earnings Growth Rate Market Cap Weighted Average 8.6%
Austria Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WBAG:IDXX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WBAG:IDXX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,927 542 3
2020-12-31 2,657 550 478 8
2019-12-31 2,413 493 421 8
WBAG:IDXX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 2,252 400 390
2018-12-31 2,213 400 377
2018-09-30 2,170 386 330
2018-06-30 2,117 386 307
2018-03-31 2,045 377 284
2017-12-31 1,969 373 263
2017-09-30 1,906 353 277
2017-06-30 1,862 343 263
2017-03-31 1,820 343 245
2016-12-31 1,775 339 222
2016-09-30 1,732 312 214
2016-06-30 1,690 289 202

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IDEXX Laboratories's earnings are expected to grow by 12.6% yearly, however this is not considered high growth (20% yearly).
  • IDEXX Laboratories's revenue is expected to grow by 9.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WBAG:IDXX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from IDEXX Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WBAG:IDXX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 6.34 6.67 6.13 3.00
2020-12-31 5.53 5.61 5.42 9.00
2019-12-31 4.82 4.87 4.77 9.00
WBAG:IDXX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 4.51
2018-12-31 4.34
2018-09-30 3.78
2018-06-30 3.51
2018-03-31 3.24
2017-12-31 3.00
2017-09-30 3.14
2017-06-30 2.96
2017-03-31 2.74
2016-12-31 2.47
2016-09-30 2.37
2016-06-30 2.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IDEXX Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IDEXX Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IDEXX Laboratories has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has IDEXX Laboratories performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IDEXX Laboratories's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IDEXX Laboratories's year on year earnings growth rate has been positive over the past 5 years.
  • IDEXX Laboratories's 1-year earnings growth exceeds its 5-year average (37.6% vs 15.9%)
  • IDEXX Laboratories's earnings growth has exceeded the Europe Medical Equipment industry average in the past year (37.6% vs 7.7%).
Earnings and Revenue History
IDEXX Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IDEXX Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WBAG:IDXX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2,251.64 390.26 635.63 120.35
2018-12-31 2,213.24 377.03 629.72 117.86
2018-09-30 2,169.98 329.65 623.33 116.53
2018-06-30 2,116.51 306.91 610.23 114.93
2018-03-31 2,044.69 283.58 596.05 112.42
2017-12-31 1,969.06 263.14 575.17 109.18
2017-09-30 1,905.93 277.26 560.70 105.79
2017-06-30 1,862.27 263.20 547.29 103.88
2017-03-31 1,819.89 245.05 533.99 102.29
2016-12-31 1,775.42 222.05 521.85 101.12
2016-09-30 1,732.11 214.03 515.75 101.20
2016-06-30 1,690.19 201.79 502.46 100.39
2016-03-31 1,636.97 191.50 492.74 99.30
2015-12-31 1,601.89 192.08 482.47 99.68
2015-09-30 1,554.17 173.69 474.97 99.05
2015-06-30 1,531.30 181.61 467.17 99.04
2015-03-31 1,508.08 181.92 456.90 100.16
2014-12-31 1,485.81 181.91 448.10 98.26
2014-09-30 1,487.92 199.20 435.14 95.89
2014-06-30 1,442.70 192.75 422.37 92.61
2014-03-31 1,405.16 189.53 409.26 89.36
2013-12-31 1,377.06 187.80 401.35 88.00
2013-09-30 1,342.52 187.90 381.09 86.56
2013-06-30 1,319.70 185.06 369.73 85.34
2013-03-31 1,302.77 182.38 361.79 83.22
2012-12-31 1,293.34 178.27 354.57 82.01
2012-09-30 1,281.00 172.92 353.38 81.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst IDEXX Laboratories made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • IDEXX Laboratories used its assets more efficiently than the Europe Medical Equipment industry average last year based on Return on Assets.
  • IDEXX Laboratories's use of capital has not improved over the past 3 years (Return on Capital Employed).
X
Past performance checks
We assess IDEXX Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IDEXX Laboratories has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is IDEXX Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IDEXX Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IDEXX Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IDEXX Laboratories's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of IDEXX Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IDEXX Laboratories Company Filings, last reported 3 months ago.

WBAG:IDXX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 51.87 1,046.33 116.62
2018-12-31 -9.23 1,000.29 123.79
2018-09-30 -1.36 1,016.92 146.88
2018-06-30 -40.85 1,040.13 174.56
2018-03-31 -48.98 1,016.51 159.23
2017-12-31 -53.84 1,261.08 471.93
2017-09-30 -48.39 1,290.40 454.10
2017-06-30 -86.11 1,304.89 422.90
2017-03-31 -73.91 1,265.87 400.34
2016-12-31 -108.21 1,204.11 391.85
2016-09-30 54.99 1,087.14 391.47
2016-06-30 -8.50 1,155.96 370.20
2016-03-31 -73.79 1,222.02 350.57
2015-12-31 -84.00 1,170.09 342.59
2015-09-30 -38.80 1,142.06 349.55
2015-06-30 8.55 1,097.80 344.02
2015-03-31 34.08 1,050.55 321.38
2014-12-31 117.59 899.00 322.54
2014-09-30 229.47 726.24 292.74
2014-06-30 452.93 535.60 305.05
2014-03-31 512.25 466.14 286.20
2013-12-31 518.21 430.22 279.06
2013-09-30 534.90 400.79 264.81
2013-06-30 549.59 371.38 251.01
2013-03-31 631.30 264.87 228.36
2012-12-31 636.26 214.50 223.99
2012-09-30 617.54 237.53 221.44
  • IDEXX Laboratories's level of debt (2017.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (91.3% vs 2017.2% today).
  • Debt is well covered by operating cash flow (38.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 15.5x coverage).
X
Financial health checks
We assess IDEXX Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IDEXX Laboratories has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is IDEXX Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IDEXX Laboratories dividends. Estimated to be 0% next year.
If you bought €2,000 of IDEXX Laboratories shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IDEXX Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IDEXX Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WBAG:IDXX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
Austria Market Average Dividend Yield Market Cap Weighted Average of 51 Stocks 3.5%
Austria Minimum Threshold Dividend Yield 10th Percentile 1%
Austria Bottom 25% Dividend Yield 25th Percentile 1.4%
Austria Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

WBAG:IDXX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IDEXX Laboratories has not reported any payouts.
  • Unable to verify if IDEXX Laboratories's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IDEXX Laboratories's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IDEXX Laboratories has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of IDEXX Laboratories's dividends in 3 years as they are not expected to pay a notable one for Austria.
X
Income/ dividend checks
We assess IDEXX Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IDEXX Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IDEXX Laboratories has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of IDEXX Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jay Mazelsky
COMPENSATION $2,897,125
AGE 58
TENURE AS CEO 0.1 years
CEO Bio

Mr. Jay Mazelsky is an Interim President and Chief Executive Officer of IDEXX Laboratories, Inc. since June 28, 2019. He served as an Executive Vice President of Companion Animal Group at IDEXX Laboratories, Inc. since 2019 until June 28, 2019 and served as Executive Vice President of since August 2012 till 2019. Mr. Mazelsky oversees the Companion Animal Group Customer Facing Organization in North America, the IDEXX VetLab in-house diagnostics, Digital Radiography and Computer Systems lines of business, the Pet Health Network Pro offering and the VetConnect PLUS and Integrated Practice strategies. Prior to joining the Company, he served as Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics, the Netherlands, a healthcare, lifestyle and lighting technologies company. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor's degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

CEO Compensation
  • Jay's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Insufficient data for Jay to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team Tenure

Average tenure and age of the IDEXX Laboratories management team in years:

3
Average Tenure
58
Average Age
  • The tenure for the IDEXX Laboratories management team is about average.
Management Team

Jay Mazelsky

TITLE
Interim President & CEO
COMPENSATION
$3M
AGE
58
TENURE
0.1 yrs

Jon Ayers

TITLE
Chairman
COMPENSATION
$7M
AGE
63

Brian McKeon

TITLE
CFO, Executive VP & Treasurer
COMPENSATION
$3M
AGE
57
TENURE
5.5 yrs

John Hart

TITLE
Corporate Vice President of Worldwide Operations
TENURE
1.8 yrs

Jeffery Chadbourne

TITLE
Senior Director of Accounting & Financial Reporting
AGE
43
TENURE
4.5 yrs

Jeffrey Thomas

TITLE
Corporate VP & Chief Technology Officer
TENURE
4.3 yrs

Ken Grady

TITLE
Corporate VP & Chief Information Officer
TENURE
3.4 yrs

Kerry Bennett

TITLE
Vice President of Investor Relations

Sharon Underberg

TITLE
Corporate VP
AGE
58
TENURE
0.3 yrs

Pat Venters

TITLE
Chief Marketing Officer & VP
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the IDEXX Laboratories board of directors in years:

5.3
Average Tenure
58
Average Age
  • The tenure for the IDEXX Laboratories board of directors is about average.
Board of Directors

Rebecca Henderson

TITLE
Independent Director
COMPENSATION
$270K
AGE
58
TENURE
16 yrs

M. Szostak

TITLE
Independent Director
COMPENSATION
$283K
AGE
68
TENURE
7 yrs

Dan Junius

TITLE
Independent Director
COMPENSATION
$280K
AGE
67
TENURE
5.3 yrs

Bruce Claflin

TITLE
Independent Director
COMPENSATION
$275K
AGE
68
TENURE
4 yrs

Lawrence Kingsley

TITLE
Lead Director
COMPENSATION
$273K
AGE
56
TENURE
1.2 yrs

Sophie Vandebroek

TITLE
Independent Director
COMPENSATION
$260K
AGE
57
TENURE
6 yrs

Stuart Essig

TITLE
Independent Director
COMPENSATION
$260K
AGE
57
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • IDEXX Laboratories individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jun 19 Sell Giovani Twigge Individual 31. May 19 31. May 19 -2,600 €224.40 €-583,441
13. May 19 Sell Michael Lane Individual 10. May 19 10. May 19 -1,812 €218.29 €-395,545
07. May 19 Sell Giovani Twigge Individual 06. May 19 06. May 19 -2,015 €223.25 €-449,849
01. Mar 19 Sell Giovani Twigge Individual 28. Feb 19 28. Feb 19 -1,500 €185.95 €-278,927
27. Feb 19 Sell Jacqueline Studer Individual 25. Feb 19 26. Feb 19 -1,373 €186.56 €-253,203
19. Feb 19 Sell Michael Lane Individual 15. Feb 19 15. Feb 19 -235 €184.50 €-43,357
19. Feb 19 Sell M. Szostak Individual 14. Feb 19 14. Feb 19 -5,906 €185.32 €-1,094,515
07. Feb 19 Sell Giovani Twigge Individual 06. Feb 19 06. Feb 19 -997 €183.76 €-183,211
07. Feb 19 Buy Lawrence Kingsley Individual 05. Feb 19 05. Feb 19 2,405 €182.95 €439,994
07. Nov 18 Sell Jacqueline Studer Individual 06. Nov 18 06. Nov 18 -3,313 €176.36 €-584,270
23. Aug 18 Sell Michael Lane Individual 21. Aug 18 21. Aug 18 -74 €211.48 €-15,649
07. Aug 18 Buy Bruce Claflin Individual 03. Aug 18 03. Aug 18 415 €208.73 €86,623
X
Management checks
We assess IDEXX Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IDEXX Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Details
Name: IDEXX Laboratories, Inc.
IDXX
Exchange: WBAG
Founded: 1983
$21,718,217,125
86,006,332
Website: http://www.idexx.com
Address: IDEXX Laboratories, Inc.
One IDEXX Drive,
Westbrook,
Maine, 04092,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IDXX Common Stock Nasdaq Global Select US USD 21. Jun 1991
DB IX1 Common Stock Deutsche Boerse AG DE EUR 21. Jun 1991
LSE 0J8P Common Stock London Stock Exchange GB USD 21. Jun 1991
WBAG IDXX Common Stock Wiener Boerse AG AT EUR 21. Jun 1991
Number of employees
Current staff
Staff numbers
8,377
IDEXX Laboratories employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 22:12
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2019/07/09
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.